Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MEIS1 antisense RNA 2 (MEIS1-AS2) is a long non-coding RNA (lncRNA), meaning it does not encode a protein and instead functions at the RNA level. It is described in some gene and reagent databases, but there is no direct evidence in the literature that MEIS1-AS2 constitutes an independent molecular target, nor is it established as a therapeutic, diagnostic, or biomarker target in current research. The entry is further complicated by alternative names overlapping with both "MEIS1-AS1" and potential confusion with the well-characterized MEIS1 protein-coding gene, a homeodomain transcription factor involved in neural development and implicated in disease, but these refer to distinct molecular entities. No disease associations, roles in biological pathways, or drug interactions specific to MEIS1-AS2 have been reported in the available references. There is inconsistency and possible ambiguity in database and commercial reagent entries regarding "MEIS1-AS2" and "MEIS1-AS1"; no robust data confirming their function or therapeutic relevance was found. The cluster of names provided (MEIS1-AS1, MEIS1 antisense RNA 1, etc.) suggests possible conflation or redundancy rather than distinct, validated RNA species. The main associated gene, MEIS1, is a protein-coding transcription factor widely studied in neural and hematopoietic development, but this is a separate and established molecular target, unlike MEIS1-AS2. In summary, MEIS1 antisense RNA 2 (MEIS1-AS2) appears in some gene and reagent catalogs, where it is designated as a long non-coding RNA, but it is not a validated therapeutic target, and its biological functions, disease roles, or clinical relevance are not established. There is also possible confusion with similar or overlapping non-coding RNA names and with the distinct MEIS1 protein-coding gene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MEIS1 antisense RNA 2 (MEIS1-AS2).